
Andrew Hill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5503865/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine, 2019, 381, 803-815.	27.0	447
2	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV,the, 2020, 7, e666-e676.	4.7	145
3	The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries. Aids, 2018, 32, 1551-1561.	2.2	96
4	Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nature Communications, 2020, 11, 5922.	12.8	55
5	Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. Aids, 2020, 34, 2259-2268.	2.2	30
6	Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. Journal of the International AIDS Society, 2019, 22, e25352.	3.0	25
7	Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. Aids, 2021, 35, S127-S135.	2.2	21
8	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. Journal of Virus Eradication, 2020, 6, 70-73.	0.5	20
9	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy. Current Opinion in Infectious Diseases, 2021, 34, 16-24.	3.1	20
10	The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/dolutegravir, 2021, 35, S117-S125.	2.2	12
11	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. Aids, 2021, 35, 205-211.	2.2	11
12	Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication. Current Opinion in HIV and AIDS, 2021, 16, 106-114.	3.8	7
13	Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. Aids, 2020, 34, 321-324.	2.2	4
14	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. Journal of Virus Eradication, 2020, 6, 70-73.	0.5	4
15	High individual pain variability in people living with HIV: A graphical analysis. European Journal of Pain, 2021, 25, 160-170.	2.8	Ο